Phaseline

Companies › Catapult Therapeutics

Catapult Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CAP-100
humanized antibody against C-C-chemokine receptor 7 (CCR7)
CCR7Phase 1Lymphocytic Leukemia, ChronicJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04704323CAP-100Phase 1Lymphocytic Leukemia, ChronicOncologyJan 2027

Targets

CCR7 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.